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Background: As supra-physiological intake of corticosteroids is a well known risk factor for the
development of adrenal insufficiency, we investigated the function of the hypothalamic-pituitary-
adrenal (HPA) axis during a 14-day course of systemic corticosteroids in patients with acute
exacerbation of chronic obstructive pulmonary disease using clinical and laboratory measures.
Methods: A systematic clinical and laboratory assessment including measurement of basal cortisol
levels and the response to low dose (1 µg) ACTH stimulation was performed in nine patients
before, on the first and the last day of treatment, as well as 2, 7 and 21 days after corticosteroid
withdrawal.
Results: At baseline, all nine patients had normal responses to 1 µg ACTH. On the first day of
steroid treatment, 78% had a blunted peak cortisol response. This percentage increased to 89%
after 14 days of steroid treatment. 78%, 33% and 33% of the patients had a blunted cortisol
response to ACTH 2, 7, and 21 days after corticosteroid withdrawal, respectively. ROC curve
analysis revealed that only basal cortisol concentrations (AUC 0.89), but not ACTH concentrations
(AUC 0.49) or clinical signs (AUC 0.47) were predictive of an impaired function of the HPA axis.
Basal cortisol levels of > 400 and < 150 nmol/l were 96% and 100% sensitive for a normal or
pathological response to the ACTH stimulation test, respectively.
Conclusion: Immediate and prolonged suppression of the HPA axis is a common finding in
otherwise asymptomatic patients undergoing systemic steroid treatment for acute exacerbation of
chronic obstructive pulmonary disease and can reliably be assessed with the low-dose ACTH test.
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Background
The administration of a 2 week course of systemic corti-
costeroids to treat patients with acute exacerbations of
chronic obstructive pulmonary disease (AECOPD) has
become common practice over the past 30 years [1]. This
practice, however, remains debated because corticoster-
oids are only modestly effective in shortening the dura-
tion of exacerbations of COPD and have serious
metabolic adverse effects including hyperglycemia, oste-
oporosis, myopathies, mental disturbances and suppres-
sion of the hypothalamic-pituitary-adrenal (HPA) axis,
among others [2].
Adrenal insufficiency often presents with only minimal
and unspecific clinical prodromal symptoms but may
suddenly become life-threatening if left untreated upon
acute stress (e.g. infection, acute exacerbation, trauma or
critical illness)[3]. Predicting adrenal insufficiency is chal-
lenging, since neither the dose nor the duration of gluco-
corticoid treatment, nor random plasma cortisol
measurements correlate with the function of the HPA axis
[4]. The insulin-induced hypoglycaemia test is the most
agreed-on reference standard for "stress" and for the veri-
fication of adrenal insufficiency [5]. The insulin tolerance
test, however, is labour-intensive, potentially dangerous
and unpleasant for the patient, and thus, not feasible out-
side an endocrine unit. In clinical practice, the simpler
low-dose corticotropin (ACTH) test is a useful and sensi-
tive substitute as it reveals partial adrenal insufficiency by
providing physiological adrenocortical stimulation [6,7].
The aim of this study was to assess occurrence and time
course of adrenal suppression in patients undergoing a 14
day course of systemic corticosteroids for AECOPD by
means of the low-dose corticotropin test.
Methods
From October 2005 to June 2006, we prospectively
included nine consecutive patients aged 40 years or older,
who were admitted to the University Hospital in Basel,
Switzerland, for acute exacerbation of COPD with >1 of
the following symptoms: increase in dyspnea, increase in
sputum, discolouration of sputum [8]. In all patients
pneumonia was excluded by chest radiograph. All patients
had a standardized steroid treatment with a single injec-
tion of 40 mg of methylprednisolone (Solumedrol®), fol-
lowed by an oral 13-day regime of 40 mg prednisone
(Prednisone®). In addition, in all patients a medical treat-
ment with inhaled long acting β2-agonists and inhaled
corticosteroids was initiated. Patients who received sys-
temic glucocorticoid treatment within the last 6 months
and patients with known Addison's disease, adrenal
metastases, Cushing's disease or pituitary adenomas were
excluded from the study.
After study inclusion, all patients were examined on 5
clinical visits, namely on days 2 and 14 (the second and
the last day of steroid treatment) and on days 16, 21 and
35, respectively. On every visit, the patients' functional
status and a clinical questionnaire, adapted from a pub-
lished clinical adrenal insufficiency score were assessed
(range 0–10 for each symptom, higher scores indicate
greater discomfort) [9]. A subset of patients (n = 5) was
asked at different time points to self-report their func-
tional status with the help of a visual analogue scale, rang-
ing from 0 (feeling extremely ill) to 100 (feeling
completely healthy).
The study was approved by the institutional review board
(Ethikkommission beider Basel, EKBB) and written
informed consent was obtained from all included
patients. All data were held and analyzed by the authors.
Prior to the initial administration of intravenous methyl-
prednisolone and in the morning of all 5 clinical visits,
low-dose (1 µg) ACTH tests were performed by a specialist
study nurse. On all occasions, blood samples were taken
at 0 min for the assessment of basal cortisol and basal
ACTH concentrations, and again 30 min after intravenous
(i.v.) administration of 1 µg corticotropin (synthetic
ACTH1–24) for the measurement of stimulated serum cor-
tisol concentrations. Based on prior studies in our Institu-
tion and the endocrine literature, a normal response to
intravenous corticotropin was defined as a stimulated
plasma cortisol concentration > 550 nmol/l [7,10-13].
Blood samples were immediately centrifuged, aliquoted,
and stored at -70°C until batch analyses. Serum total cor-
tisol was measured using a chemiluminescence immu-
noassay (DPC®  Diagnostic Products Corporation, Los
Angeles, CA) with a calculated sensitivity of 13.8 nmol/l.
The intra-assay coefficient of variation was 4.4%, and the
inter-assay coefficient of variation was 11.0%. Serum
ACTH was measured using a chemiluminescence immu-
noassay (DPC® Diagnostic Products Corporation) with a
sensitivity of 1 ng/l.
To evaluate differences between groups, the Mann-Whit-
ney U test and the Wilcoxon signed rank sum test for not
normally distributed unpaired and paired variables, and
the Fisher's exact test for categorical variables were used, as
appropriate. To compare the prognostic value of individ-
ual laboratory markers for predicting HPA insufficiency as
assessed by the corticotropin test, a receiver operating
characteristic (ROC) analysis was performed [14]. The
area under the ROC curve (AUC) was the measure of the
accuracy of the laboratory parameter to distinguish the
groups. A p-value <0.05 (for a 2-sided test) was considered
statistically significant. All calculations were performed
using Stata 9.2 (Stata Corp, College Station, Tex).BMC Pulmonary Medicine 2008, 8:1 http://www.biomedcentral.com/1471-2466/8/1
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Results
Baseline characteristics
We included nine steroid-naive patients (3 women, 6
men) with a median duration of COPD of 2 years (IQR 1–
4) and a median of 1 (IQR 1–2) hospital admission for
exacerbation per year. Seven patients were on medical
treatment for COPD on admission, including inhaled
short- and/or long acting β2-agonists and/or anticholiner-
gics (78%) and inhaled corticosteroids (56%). None of
the patients was admitted to the ICU or was in need of
mechanical ventilation. The detailed baseline characteris-
tics, clinical findings and laboratory data on admission
are presented in Table 1.
Adrenal function test
Figure 1 shows the basal and the stimulated cortisol con-
centrations and the corresponding basal ACTH values for
all patients on baseline, before the initiation of steroid
therapy, and in the morning of the five clinical visits.
Compared to baseline (712 (95%CI 627–771)), median
stimulated cortisol measurements were significantly lower
on days 2, 14, 16 and 35 (453 (95%CI 438–529), p =
0.008; 298 (95%CI 177–461), p = 0.008; 427 (95%CI
307–579), p = 0.008 and 566 (95%CI 447–668), p =
0.04). In addition, median basal cortisol measurements
439 (95%CI 320–562)) were significantly lower on days
2 and 14 (200 (95%CI 124–259), p = 0.008 and 112
(95%CI 58–211), p = 0.007).
Table 1: Baseline values for all patients (n = 9)
Baseline characteristics
Gender (female/male) 3/6
Age (years)* 72 (51–86)
Body-mass index (kg/m2)* 25.9 (24.7–33.7)
Smoking (pack years)* 30 (25–50)
Duration of COPD (years)* 2.0 (1–4)
Number of AECOPD in previous year* 1 (1–2)
Duration of AECOPD (days) 4 (4–7)
Dyspnea (%) 9 (100%)
Cough (%) 9 (100%)
Increased sputum production (%) 9 (100%)
Discoloured sputum (%) 7 (78%)
Fever (%) 7 (78%)
Maintenance therapy at admission (%)
β2-agonist and/or anticholinergic 7 (78%)
Inhaled corticosteroids 4 (44%)
Oral corticosteroids 0 (0%)
Theophyllin 0 (0%)
Long-term oxygen therapy 1 (11%)
Severity of AECOPD – Anthonisen's criteria [8] (%)
1 0 (0%)
2 2 (22%)
3 7 (78%)
Heart rate* (beats/min) 84 (70–101)
Blood pressure* (mmHg)
Systolic 143 (120–150)
Diastolic 80 (69–85)
Respiratory rate* 16 (12–25)
Laboratory findings:
Leukocytes total* 9.3 (7.7–10.1)
CRP (mg/dl)* 19 (6–61)
Cortisol basal (nmol/l)** 439 (392–462)
Cortisol after 1 µg ACTH (nmol/l)** 712 (608–730)
Basal ACTH (ng/l)** 9.2 (5.1–11.5)
* median, interquartile range;BMC Pulmonary Medicine 2008, 8:1 http://www.biomedcentral.com/1471-2466/8/1
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Before the initiation of steroid therapy, all patients
(100%) had a normal rise of cortisol after injection of 1 µg
ACTH defined as a stimulated cortisol value > 550 nmol/
l [7,11,12]. On the first day of steroid treatment, 78% of
patients had a blunted peak cortisol response. This per-
centage increased to 89% after 14 days of steroid treat-
ment. 78%, 33% and 33% of the patients had a blunted
cortisol response to 1 µg ACTH injection, 2, 5, and 14 days
after corticosteroid withdrawal, respectively.
Median basal plasma cortisol (nmol/l) concentrations
were significantly higher in patients with a normal adre-
nal response as compared to patients with a suppressed
adrenal response (409 (95%CI 366–482) vs 142 (IQR
129–218)), p  < 0.0001). Median ACTH concentrations
(pmol/ml) were similar on baseline as compared to the 5
clinical visits (p > 0.05 for each measurement) and for all
patients with normal and insufficient rise of cortisol after
injection of 1 µg ACTH (14.4 (95%CI 11.3–21.7) vs 8.6
(95%CI 8.3–16.1), p = 0.1).
Clinical data
The symptom score suggestive of adrenal insufficiency
was not discriminative for all 6 time points and among
patients with normal and inadequate rise of cortisol in the
ACTH test (Table 2 and Figure 2) [9]. The self-reported
functional status assessed by the visual analogue scale on
the different clinical visits did not significantly differ
between clinical visits and time points of normal and
pathological stimulated cortisol values, respectively (data
not shown).
Prediction of adrenal insufficiency
To compare the predictive value of different parameters
(e.g. basal cortisol, basal ACTH, the cortisol/ACTH ratio,
the clinical symptom score and the visual analogue scale)
we pooled the data of all nine patients and visits, and per-
formed ROC plot analysis (Figure 3). Sensitivity was cal-
culated with those patients and time points, where the
low dose corticotropin stimulation test was inadequate (n
= 28) and specificity was assessed with those patients and
time points, where it was normal (n = 25) (defined as rise
of cortisol > 550 mmol/l after injection of 1 µg ACTH).
The area under the ROC curve (AUC) to predict adrenal
insufficiency revealed an AUC for basal cortisol of 0.91
(95%CI 0.85–0.99), which was better than for ACTH
(0.63 (95%CI 0.48–0.79)), the ACTH/cortisol ratio (0.79
(95%CI 0.67–0.91)), the clinical symptoms score (0.51
(95%CI 0.34–0.68)) and the visual analogue scale (0.45
(95%CI 0.23–0.66)). Basal cortisol levels of > 400 and <
150 nmol/l were 96% and 100% predictive for a normal
or pathological response to the ACTH stimulation test
(Table 3). Serum ACTH levels and the ACTH/cortisol ratio
did not improve the predictive accuracy of basal cortisol
measurement alone.
Discussion
Patients prescribed an oral and inhaled corticosteroid are
at a dose related increased risk of adrenal crisis as illus-
trated in a recently published epidemiological case con-
trol study of 154 reported cases in the general population
[15]. The magnitude of the risk for an individual patient
with oral and inhaled corticosteroids for AECOPD, how-
ever, has not yet been determined and is often neglected
in common practice [16]. A sensitive measure to assess the
functional status of the HPA-axis, and thus the risk for
Addisonian crises upon stress, is the low-dose ACTH-test.
In this study, even short-term low-dose courses of sys-
temic corticosteroids for the treatment of AECOPD in ster-
oid naive patients was associated with a measurable and
prolonged suppression of the HPA-axis in the majority of
patients. Importantly, clinical signs and symptoms are
unreliable and unable to predict an impairment of the
HPA-axis. Accordingly, in patients with AECOPD receiv-
ing systemic corticosteroids the presence of adrenal insuf-
ficiency should be considered.
(a) Cortisol values basal (black) and after stimulation with 1  µg corticotropin (grey) and (b) corresponding basal ACTH  concentrations for all patients at six clinical visits Figure 1
(a) Cortisol values basal (black) and after stimulation with 1 
µg corticotropin (grey) and (b) corresponding basal ACTH 
concentrations for all patients at six clinical visits.BMC Pulmonary Medicine 2008, 8:1 http://www.biomedcentral.com/1471-2466/8/1
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Physiologically, the hypothalamus secretes corticotropin
releasing hormone (CRH), which stimulates the release of
adrenocorticotropic hormone (ACTH) from the pituitary
gland. ACTH leads to the release of cortisol through stim-
ulation of the adrenal cortex, which in turn has a negative
feedback on CRH and ACTH. Administration of exoge-
nous corticosteroids, even in small doses for only few
days, leads to a measurable suppression of the HPA-axis
resulting in the inability of the adrenal cortex to secrete
additional cortisol if needed [17]. One might argue that
laboratory changes in the HPA axis after short-term sys-
temic steroid therapy are not of clinical relevance. Indeed,
the absolute risk of adrenal crisis after cessation of oral
and inhaled corticosteroids might be considered rare
based on the literature, but is likely to be substantially
underreported in clinical practice [15]. Importantly, the
manifestation and the severity of clinical signs depend on
the presence of stress with its resulting increased cortisol
demand. Upon major stress, even a mild adrenal insuffi-
ciency can be hazardous leading to hemodynamic insta-
bility, vasoactive-refractory shock and ultimatively death
[3,15,18]. Consequently, in adrenal insufficiency admin-
istration of systemic corticosteroids (preferably hydrocor-
tisone) is mandatory and potentially lifesaving.
Unfortunately, symptoms of adrenal insufficiency are
highly variable and only occur if the patient is experienc-
Table 2: Baseline cortisol concentration, cortisol concentration after stimulation with 1 µg corticotropin and clinical data of all 9 
patients and all 6 clinical visits.
Patient Nr. Laboratory and clinical parameters Clinical visits
V0 V1 V2 V3 V4 V5
1 Cortisol basal* 552 255 264 689 NA 543
Cortisol stimulated* 887 572 467 803 NA 770
Clinical score 6 4 0 0 NA 40
2 Cortisol basal* 162 153 112 53.2 53.1 36.8
Cortisol stimulated* 603 582 355 277 368 401
Clinical score 48 36 31 36 24 42
3 Cortisol basal* 439 156 69.2 149 261 416
Cortisol stimulated* 753 448 101 238 448 566
Clinical score 60 33 17 16 11 5
4 Cortisol basal* 404 66.6 121 157 352 373
Cortisol stimulated* 608 422 451 405 671 587
Clinical score 28 61 66 52 71 68
5 Cortisol basal* 392 200 112 461 385 409
Cortisol stimulated* 584 453 298 553 600 610
Clinical score 0 6 3 4 6 6
6 Cortisol basal* 462 82.6 50.1 365 319 299
Cortisol stimulated* 726 429 233 427 468 557
Clinical score 34 24 31 16 25 28
7 Cortisol basal* 750 332 27.0 121 629 229
Cortisol stimulated* 730 496 46.5 273 752 415
Clinical score 66 36 32 28 62 30
8 Cortisol basal* 458 204 115 411 354 136
Cortisol stimulated* 689 452 282 501 615 365
Clinical score 6 0 6 4 2 2
9 Cortisol basal* 353 275 331 394 490 490
Cortisol stimulated* 712 498 637 512 664 746
Clinical score 42 44 8 14 22 24
*(nmol/l)BMC Pulmonary Medicine 2008, 8:1 http://www.biomedcentral.com/1471-2466/8/1
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ing more or less severe stress. Therefore, predicting or
excluding the risk for adrenal insufficiency from clinical
parameters, as often falsely done, is delicate and poten-
tially dangerous. Illustratively, typical symptoms of adre-
nal insufficiency (e.g. weakness, low blood pressure and
hypoglycemia) were completely nonspecific in this study
and were, thus, unreliable predictors of adrenal insuffi-
ciency. This should be kept in mind before an absence of
adrenal insufficiency is postulated based on the absence
of signs and symptoms by the treating physician.
Based on our data and supported by the literature, basal
cortisol levels are helpful to diagnose adrenal insuffi-
ciency in a subset of patients, i.e. if cortisol values are <
150 or > 400 nmol/l adrenal insufficiency is highly likely
or can be excluded, respectively. Measurement of basal
ACTH concentration did not improve the diagnostic accu-
racy. This is not surprising because of the pulsatile secre-
tion of ACTH.
In asthmatic patients, the various adverse effects of oral
and even inhaled corticosteroids on the HPA axis, includ-
ing adrenal crisis, have been well recognized [18,19]. In
patients receiving systemic corticosteroids for acute exac-
erbation of COPD, the frequency and duration of adrenal
suppression has not prospectively been investigated. Sur-
prisingly, in common practice, a so called "short-term" 14
days course of systemic corticosteroids is generally consid-
ered safe and the potential consequences of adrenal sup-
pression are often neglected [16]. In our patients, adrenal
stimulation tests revealed a suppressed adrenal response
to corticotropin in 7 out of 9 patients after only one day
of treatment and in 8 out of 9 patients after the 2 weeks
course. Similar proportions have been reported from stud-
ies on longer-term glucocorticoid treatment [20]. The
observed gradual recovery of the suppressed adrenal
response to the low-dose corticotropin test was heteroge-
neous among the patients lasting from a few days to up to
3 weeks after withdrawal. In individual patients, it is not
possible to predict the duration of the HPA axis recovery,
though, careful instruction and observation of these
patients and examination for potential adrenal insuffi-
ciency should be recommended.
This study has limitations. Firstly, we have only included
a small, but well defined number of patients to assess the
adrenal response after steroid treatment for AECOPD. The
number of performed tests is too small to recommend
definitive cut-off levels for peak cortisol concentrations
during acute illnesses. Secondly, our population varied in
respect to the use of inhaled corticosteroids on admission,
which is a known risk factor for adrenal insufficiency.
However, all patients had a normal ACTH stimulation test
at baseline and the inhaled medical treatment with
inhaled long acting β2-agonists and corticosteroids after
study inclusion was uniform. Still, the impact of inhaled
corticosteroids can not be addressed with this study.
Thirdly, we did not directly assess free cortisol values or albu-
min or cortisol binding globulin concentrations to calculate free
cortisol levels. Depending on the severity and kinetic of
ROC curve analysis to predict adrenal insufficiency for basal  cortisol, ACTH, the cortisol/ACTH ratio and the clinical  score Figure 3
ROC curve analysis to predict adrenal insufficiency for basal 
cortisol, ACTH, the cortisol/ACTH ratio and the clinical 
score.
Clinical symptom score in patients with normal (● ) and inad- equate (▲ ) response to the 1 µg corticotropin test for each  visit Figure 2
Clinical symptom score in patients with normal (● ) and inad-
equate (▲ ) response to the 1 µg corticotropin test for each 
visit. The clinical score asks patients for fatigue, hypoglycemia 
(hypoglycemic symptoms or fasting glucose < 3,5 mmol), loss 
of energy, orthostatic disturbance or hypotonia (systolic 
blood pressure < 100 mmHg, diastolic blood pressure < 60 
mmHg), reduced strength, sleep disturbance, muscle pain, 
mood changes (feeling depressed), nausea, concentration dis-
turbance, weight loss (> 3 kg), stomach pain, hyperpigmenta-
tion and eosinophila (> 330 cells/ml) [9].BMC Pulmonary Medicine 2008, 8:1 http://www.biomedcentral.com/1471-2466/8/1
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acute disease, total and free cortisol levels may show dis-
cordant results and total cortisol levels may not ade-
quately anticipate the free cortisol levels needed during
severe peracute stress [21].
Conclusion
In conclusion, short-term, low-dose systemic steroid treat-
ment for AECOPD exposes the patients to the risk of adre-
nal insufficiency. During the period of recovery the
function of the adrenal response to stress may still be
impaired. In a minority of patients the adrenal response
even remained suppressed for several weeks. If patients
are exposed to stress after such treatment, adrenal func-
tion should be assessed.
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